Amid National Volume-Based Procurement of Sutures, Distributors Face Strategic Crossroads: Shandong Haideke Emerges as a Preferred Partner

Under the centralized procurement rules, medical institutions must select and confirm their agreed purchase volumes for the next three years from the list of winning bid products during the window period from January 19 to February 2, taking into account actual clinical usage. For distributors, this is not merely a matter of price selection, but rather a systematic assessment of supply stability, product competitiveness, clinical acceptance, and long-term partnership potential. Choosing the right brand means securing a growth trajectory for the next three years.

In this centralized procurement round, Shandong Haidike secured 100% of the fixed contracted volume with its dual-thread product line featuring both absorbable and non-absorbable sutures, and further qualified for the allocation of remaining volumes, emerging as a first-mover and leader in the domestic suture market. This outstanding performance is not merely an entry ticket but also serves as a priority pass for distributors in subsequent volume allocations. Consequently, Haidike has become the most compelling choice for distributors today—because Haidike understands the market, clinical practice, and, most importantly, the core needs of distributors, delivering one-stop solutions through comprehensive hard-core capabilities.

Following centralized procurement, consumables have become a core cost item for hospitals. Under the cost-containment pressure of DIP/DRG payment systems, clinical selection will favor winning bid products that rank higher and offer superior cost-effectiveness. Brands lacking competitiveness risk seeing all prior relationship-building efforts come to naught.

Haideke has firmly established itself in the first tier of centralized procurement. By securing qualification to compete for over 20 million units of unallocated volume in both absorbable and non-absorbable synthetic materials, its high ranking naturally positions the brand prominently on hospital preference lists. Leveraging highly competitive pricing advantages that align with the core “volume-for-price” logic of centralized procurement, and responding to national DRG/DIP payment reforms, Haideke has become a benchmark choice for hospital consumable procurement. This ensures that every investment made by distributors translates into tangible sales, establishing a clear, efficient, and sustainable market pathway.

Product quality is the cornerstone of market confidence; products that fail to earn physicians’ trust will struggle to sustain procurement, even after hospital listing. Haideke alleviates all clinical concerns with its globally recognized hard power: it holds five major international certifications—China NMPA, US FDA, EU CE, Brazil BGMP, and Russia RZN—exports to more than 160 countries and regions worldwide, and has entered numerous Grade A tertiary hospitals across China. Furthermore, the company is certified under three management systems—ISO 13485, ISO 14001, and ISO 45001—adhering to international standards throughout the entire process. Rigorous quality control is implemented from raw material procurement to finished goods dispatch, resulting in a defect rate approaching zero and quality stability that has been extensively validated by the market.

Haidike is one of the few companies worldwide to master core proprietary technologies in surgical needle manufacturing, achieving fully independent, end-to-end production from “a single steel wire to a finished needle,” thereby eliminating quality fluctuations associated with outsourced needle sources. Its exclusive Gold Needle series prevents blood adhesion and enhances intraoperative visibility. As the first company to offer PGLA sutures paired with black needles, Haidike significantly improves needle-holding visibility for surgeons in complex lighting conditions typical of laparoscopic and thoracoscopic procedures, markedly reducing needle placement errors. Through continuous micro-innovations, Haidike is redefining surgical precision and truly earning trust in the operating room.

“Winning the bid but failing to supply” is a core pain point for distributors, leaving hospitals with no recourse for restocking; this results not only in lost orders but also in damage to precious channel credibility. The centralized procurement alliance spanning 24 provinces features extensive coverage and large purchase volumes, testing not only product competitiveness but also the robustness of supply chain capabilities. As needle manufacturing is a critical link, Haideke’s advantages across its entire industrial chain are fully demonstrated.

Haidike boasts intelligent manufacturing bases and advanced production lines. It has formulated a specialized inventory plan tailored to the requirements of this volume-based procurement, supported by an efficient logistics and distribution network. Its fully autonomous supply chain delivers exceptional production flexibility and cost control, ensuring stable, timely, and sufficient supply even during peak order periods, while alleviating distributors’ stocking pressures. This truly realizes the principle of “easy to win the bid, easier to ensure supply,” thereby solidifying the supply foundation for business cooperation.

Centralized procurement is not the end of profitability, but the starting point for exchanging volume for profit and achieving long-term win-win outcomes. Without reasonable profit margins, partnerships cannot be sustained. Haidike achieves full autonomous control from raw materials to finished products, eliminates intermediate links, optimizes costs by leveraging its core advantage of a complete industrial chain, and directly passes this advantage on to its partners.

Leveraging the sustained order security from secondary volume increases driven by high-tier positioning, Haidike reserves a robust profit margin for distributors. This is complemented by flexible supply policies and comprehensive after-sales support. The company’s integrated regulatory system features streamlined issue-resolution processes and efficient decision-making feedback, enabling rapid response from the production floor to the hospital. This approach not only reduces distributors’ market promotion costs but also ensures stable returns, facilitating effortless market expansion and sustainable development.

Haidike has deeply cultivated the high-end medical device sector, with its product portfolio comprehensively covering three major areas: suturing, stapling, and closure. The company holds nearly one hundred registration certificates for Class I, II, and III medical devices. In the suture category alone, it offers eight core material types, including absorbable/non-absorbable and monofilament/multifilament options, precisely meeting the surgical needs of various departments such as general surgery, orthopedics, cardiovascular surgery, ophthalmology, and dentistry. This enables hospitals to overcome the pain points of multi-supplier procurement and achieve an efficient “one surgery, one suture kit” procurement model.

Meanwhile, Headico has established a dual-brand matrix, benchmarking against top-tier imported brands. By focusing on “differentiated manufacturing + customized services,” it penetrates all levels of the healthcare market. Whether for primary care institutions or Grade A tertiary hospitals, suitable product solutions are available, thereby expanding market boundaries for distributors and creating a more competitive product portfolio.

As a National High-Tech Enterprise, a Shandong Province “Gazelle Enterprise,” and a Shandong Province Specialized, Refined, Differential, and Innovative (SRDI) Small and Medium-sized Enterprise, Haidike also operates multiple provincial and municipal research platforms and key engineering laboratories. Leveraging its outstanding innovation capabilities, the company has successively showcased the power of Chinese intelligent manufacturing at major international events such as the Beijing Winter Olympics and the Xi’an National Games, demonstrating both strong brand strength and high industry recognition.

Shandong Haidike Medical Products Co., Ltd. emphasizes the integration of industry, academia, and research. It has established a Postdoctoral Innovation Practice Base in Shandong Province and has been deeply engaged in the research and development of core technologies in the medical device field for over two decades. The company possesses multiple scientific research and innovation platforms, including the Provincial Collaborative Innovation Center for Laser Green Intelligent Manufacturing Technology and Equipment, the Shandong Provincial Enterprise Technology Center, and the Shandong Provincial Suture Needle and Thread Laboratory. It features a comprehensive system integrating scientific research platforms, industrialization resources, and talent support.

Heidike’s investment in the world’s first “novel biodegradable zinc-alloy surgical staples and laparoscopic staplers” has recently achieved a key milestone, with the formal launch of a multicenter registration clinical trial in collaboration with Xinhua Hospital Affiliated to Shanghai Jiao Tong University. This innovative project is led by the team of Academician Ding Wenjiang and Professor Yuan Guangyin from Shanghai Jiao Tong University, jointly advancing the independent research and development and industrialization of high-end domestically produced surgical stapling devices.

Clinical usage habits and patient word-of-mouth feedback are the core determinants of procurement volume and contract renewal. With its comprehensive strengths in high ranking, superior quality, stable supply, favorable profit margins, and a full product portfolio, Headico ensures ease of use for physicians and peace of mind for patients, making repeat procurement and subsequent contract renewals inevitable. In the suture market landscape over the next three years, let us firmly grasp Headico, this “premium Chinese needle,” and together stitch out a blueprint for growth in the coming three years!